Andere Sprachen Aurinia Pharmaceuticals Inc.

Aktien

A1W7D4

CA05156V1022

AUPH

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 02.05.2024			% 5 Tage	% 1. Jan.
5,17 ^USD	-0,58 %		+6,16 %	-42,49 %

02.05.	Aurinia Pharmaceuticals Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
02.05.	Aurinia Pharmaceuticals Inc. bekräftigt Umsatzprognose für das Geschäftsjahr 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M	02.05.
Aurinia: Q1 Earnings Snapshot	02.05.
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02.05.
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results	02.05.
Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for the Fiscal Year 2024	02.05.
AURINIA PHARMACEUTICALS - THE U.S. FOOD & DRUG ADMINISTRATION APPROVES UPDATED LUPKYNIS LABEL TO INCLUDE LONG-TERM DATA FROM THE AURORA CLINICAL PROGRAM	01.05.
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month	01.05.
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program	30.04.
Aurinia Pharmaceuticals Inc. Announces The U.S. Food & Drug Administration Approves Updated LUPKYNIS® Label to include Long-Term Data from the AURORA Clinical Program	30.04.
UPDATE, NEW AURINIA PRESENTATION DETAILS AT THE 2024 BLOOM BURTON & CO. HEALTHCARE INVESTOR CONFERENCE	17.04.
New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference	16.04.
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024	15.04.
Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference	09.04.
ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	20.03.
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	07.03.
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	07.03.
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program	29.02.
Aurinia to Participate in Upcoming Investor Healthcare Conferences	27.02.
Sector Update: Health Care Stocks Higher Late Afternoon	15.02.
Sector Update: Health Care Stocks Higher Thursday Afternoon	15.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Aurinia Pharmaceuticals Inc.

Aktien

A1W7D4

CA05156V1022

AUPH

Andere Sprachen

Filter